Finance

Lists
Why is LRMR up ၇.၅၃%?
Dive Deeper
LRMR:NASDAQ
Larimar Therapeutics Inc
၃.၂၂ US$
+၇.၅၃%
(+၀.၂၂) 1D
နို ၁၈, GMT-၅ ၁၅:၀၂:၄၀  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for LRMR...
Open
၂.၉၅ US$
High
၃.၃၅ US$
Low
၂.၉၃ US$
Mkt. cap
၃၃.၆၄ ကုဋေ
Avg. vol.
၁.၅၅ သန်း
Volume
၁.၁၁ သန်း
52-wk high
၆.၄၂ US$
52-wk low
၁.၉၂ US$
EPS
-၁.၆၈ US$
Beta
၀.၇၃
Shares outstanding
၁၀.၄၆ ကုဋေ
No. of employees
၇၁
Open
၂.၉၅ US$
High
၃.၃၅ US$
Low
၂.၉၃ US$
Mkt. cap
၃၃.၆၄ ကုဋေ
Avg. vol.
၁.၅၅ သန်း
Volume
၁.၁၁ သန်း
52-wk high
၆.၄၂ US$
52-wk low
၁.၉၂ US$
EPS
-၁.၆၈ US$
Beta
၀.၇၃
Shares outstanding
၁၀.၄၆ ကုဋေ
No. of employees
၇၁
News stories
From web sources and news partners
Investing.com Canada
Investing.com Canada
·
ပြီးခဲ့သည့် ၅ နာရီ
Leerink reiterates Larimar Therapeutics stock rating at Outperform By Investing.com
kare11.com
kare11.com
·
ပြီးခဲ့သည့် ၂ ရက်
Larimar: Q3 Earnings Snapshot
About Larimar Therapeutics Inc
CEO-
Employees၇၁
Founded၂၀၀၅
HeadquartersBala Cynwyd, ပင်ဆယ်ဗေးနီးယားပြည်နယ်, ယူနိုက်တက်စတိတ်
SectorHealth Care
Industry-
Analyst ratings
Based on 5 analysts giving stock ratings to LRMR in the past 3 months
Strong buy
Buy
5
Hold
0
Sell
0
12-month forecast
Based on 5 Wall Street analysts offering 12 month price targets for LRMR in the last 3 months.
Highest
Current ၃.၂၂ US$
၂၅.၀၀ US$ (+၆၇၇.၆၀%)
Average
၁၄.၂၅ US$ (+၃၄၃.၂၃%)
Lowest
၉.၀၀ US$ (+၁၇၉.၉၄%)
Analyst
Recommendation
Action
Price target
Projected
Date
Jim Kelly
Leerink Partners
Buy
Maintained
၁၃.၀၀ US$
+၃၀၄.၄%
11/17/2026
Laura Chico
Wedbush
Buy
Maintained
၉.၀၀ US$
+၁၇၉.၉%
11/17/2026
Tessa Romero
J.P. Morgan
Buy
Maintained
-
-
11/09/2026
Ram Selvaraju
H.C. Wainwright
Buy
Reiterated
၁၀.၀၀ US$
+၂၁၁%
11/10/2026
Francois Brisebois
LifeSci Capital
Buy
Maintained
၂၅.၀၀ US$
+၆၇၇.၆%
09/28/2026
Basma Radwan
Leerink Partners
Buy
Maintained
၁၃.၀၀ US$
+၃၀၄.၄%
09/14/2026
Unknown Analyst
Leerink Partners
Buy
Maintained
၁၃.၀၀ US$
+၃၀၄.၄%
09/14/2026
Myles Minter
William Blair
Buy
Maintained
-
-
08/05/2026
Christopher Chen
Robert W. Baird
Buy
Maintained
၅.၀၀ US$
+၅၅.၅%
06/30/2026
Samantha Semenkow
Citi
Buy
Maintained
၁၄.၀၀ US$
+၃၃၅.၅%
06/30/2026
Catherine Novack
JonesTrading
Buy
Maintained
၁၃.၀၀ US$
+၃၀၄.၄%
02/24/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
၂၀၂၅ စက်
၂၀၂၅ ဒီ
၂၀၂၆ မတ်
၂၀၂၆ ဇွန်
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
၄.၄၈ ကုဋေ
၅.၉၂ ကုဋေ
၂.၄၉ ကုဋေ
၂.၇၈ ကုဋေ
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
၄.၆၇ သန်း
၄.၈၄ သန်း
၆.၁၉ သန်း
၆.၅၅ သန်း
Operating expense
၄.၉၅ ကုဋေ
၆.၄၀ ကုဋေ
၃.၁၁ ကုဋေ
၃.၄၄ ကုဋေ
Total operating expenses
၄.၉၅ ကုဋေ
၆.၄၀ ကုဋေ
၃.၁၁ ကုဋေ
၃.၄၄ ကုဋေ
Operating income
-၄.၉၅ ကုဋေ
-၆.၄၀ ကုဋေ
-၃.၁၁ ကုဋေ
-၃.၄၄ ကုဋေ
Other non operating income
၁.၇၉ သန်း
၁.၅၂ သန်း
၁.၅၀ သန်း
၁.၅၇ သန်း
EBT including unusual items
-၄.၇၇ ကုဋေ
-၆.၂၅ ကုဋေ
-၂.၉၆ ကုဋေ
-၃.၂၈ ကုဋေ
EBT excluding unusual items
-၄.၇၇ ကုဋေ
-၆.၂၅ ကုဋေ
-၂.၉၆ ကုဋေ
-၃.၂၈ ကုဋေ
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-၄.၇၇ ကုဋေ
-၆.၂၅ ကုဋေ
-၂.၉၆ ကုဋေ
-၃.၂၈ ကုဋေ
Net profit margin
-
-
-
-
Earnings per share
-၀.၆၁
-၀.၇၃
-၀.၃၁
-၀.၃၀
Interest and investment income
-
-
-
-
Interest expense
-
-
-
-
Net interest expenses
-
-
-
-
Depreciation and amortization charges
-
-
-
-
EBITDA
-၄.၉၄ ကုဋေ
-၆.၃၉ ကုဋေ
-၃.၁၁ ကုဋေ
-၃.၄၃ ကုဋေ
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google အက်ပ်များ